TTAC-0001, a human monoclonal antibody targeting VEGFR-2/KDR, blocks tumor angiogenesis

References

• Folkman J. Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med 1995; 1:27-31; PMID:7584949; http://dx.doi.org/10.1038/nm0195-27
   PubMed Web of Science ®Google Scholar
• Kerbel RS. Tumor angiogenesis: past, present and the near future. Carcinogenesis 2000; 21:505-15; PMID:10688871; http://dx.doi.org/10.1093/carcin/21.3.505
   PubMed Web of Science ®Google Scholar
• Carmeliet P. Angiogenesis in health and disease. Nat Med 2003; 9:653-60; PMID:12778163; http://dx.doi.org/10.1038/nm0603-653
   PubMed Web of Science ®Google Scholar
• Rafii S, Lyden D, Benezra R, Hattori K, Heissig B. Vascular and haematopoietic stem cells: novel targets for anti-angiogenesis therapy? Nat Rev Cancer 2002; 2:826-35; PMID:12415253; http://dx.doi.org/10.1038/nrc925
   PubMed Web of Science ®Google Scholar
• Ferrara N. VEGF: an update on biological and therapeutic aspects. Curr Opin Biotechnol 2000; 11:617-24; PMID:11102799; http://dx.doi.org/10.1016/S0958-1669(00)00153-1
   PubMed Web of Science ®Google Scholar
• Ferrara N. Vascular endothelial growth factor and the regulation of angiogenesis. Recent Prog Horm Res 2000; 55:15-35; PMID:11036931
   PubMedGoogle Scholar
• Blume-Jensen P, Hunter T. Oncogenic kinase signaling. Nature 2001; 411:355-65; PMID:11357143; http://dx.doi.org/10.1038/35077225
   PubMed Web of Science ®Google Scholar
• Ferrara N. Vascular endothelial growth factor as a target for anticancer therapy. Oncologist 2004; 9 1:2-10; PMID:15178810; http://dx.doi.org/10.1634/theoncologist.9-suppl_1-2
   PubMed Web of Science ®Google Scholar
• Lu D, Kussie P, Pytowski B, Persaud K, Bohlen P, Witte L, Zhu Z. Identification of the residues in the extracellular region of KDR important for interaction with vascular endothelial growth factor and neutralizing anti-KDR antibodies. J Biol Chem 2000; 275:14321-30; PMID:10799512; http://dx.doi.org/10.1074/jbc.275.19.14321
   PubMed Web of Science ®Google Scholar
• Popkov M, Jendreyko N, Gonzalez-Sapienza G, Mage RG, Rader C, Barbas III CF. Human/mouse cross-reactive anti-VEGF receptor 2 recombinant antibodies selected from an immune b9 allotype rabbit antibody library. J Immunol Methods 2004; 288:149-64; PMID:15183093; http://dx.doi.org/10.1016/j.jim.2004.03.005
   PubMed Web of Science ®Google Scholar
• Dias S, Hattori K, Heissig B, Zhu Z, Wu Y, Witte L, Hicklin DJ, Tateno M, Bohlen P, Moore MA., et al. Inhibition of both paracrine and autocrine VEGF/VEGFR-2 signaling pathways is essential to induce long-term remission of xenotransplanted human leukemias. Proc Natl Acad Sci U S A 2001; 98:10857-62; PMID:11553814; http://dx.doi.org/10.1073/pnas.191117498
   PubMed Web of Science ®Google Scholar
• Aesoy R, Sanchez BC, Norum JH, Lewensohn R, Viktorsson K, Linderholm B. An autocrine VEGF/VEGFR-2 and p38 signaling loop confers resistance to 4-hydroxytamoxifen in MCF-7 breast cancer cells. Mol Cancer Res 2008; 6:1630-8; PMID:18922978; http://dx.doi.org/10.1158/1541-7786.MCR-07-2172
   PubMed Web of Science ®Google Scholar
• Sher I, Adham SA, Petrik J, Coomber BL. Autocrine VEGF-A/KDR loop protects epithelial ovarian carcinoma cells from anoikis. Intl J Cancer 2009; 124:553-61; PMID:9004006; http://dx.doi.org/10.1002/ijc.23963
   PubMed Web of Science ®Google Scholar
• Prewett M, Huber J, Li Y, Santiago A, O'Connor W, King K, Overholser J, Hooper A, Pytowski B, Witte L., et al. Antivascular endothelial growth factor receptor (fetal liver kinase 1) monoclonal antibody inhibits tumor angiogenesis and growth of several mouse and human tumors. Cancer Res 1999; 59:5209-18; PMID:10537299
   PubMed Web of Science ®Google Scholar
• Millauer B, Shawver LK, Plate KH, Risaui W, Ullrich A. Glioblastoma growth inhibited in vivo by a dominant-negative Flk-1 mutant. Nature 1994; 367:576-9; PMID:8107827; http://dx.doi.org/10.1038/367576a0
   PubMed Web of Science ®Google Scholar
• Kuo CJ, Farnebo F, Yu EY, Christofferson R, Swearingen RA, Carter R, von Recum HA, Yuan J, Kamihara J, Flynn E., et al. Comparative evaluation of the antitumor activity of antiangiogenic proteins delivered by gene transfer. Proc Natl Acad Sci U S A 2001; 98: 4605-10; PMID:11274374; http://dx.doi.org/10.1073/pnas.081615298
   PubMed Web of Science ®Google Scholar
• Saleh M, Stacker SA, Wilks AF. Inhibition of growth of C6 glioma cells in vivo by expression of antisense vascular endothelial growth factor sequence. Cancer Res 1996; 56:393-401; PMID:8542597
   PubMed Web of Science ®Google Scholar
• Fong GH, Rossant J, Gertsenstein M, Breitman ML. Role of the Flt-1 receptor tyrosine kinase in regulating the assembly of vascular endothelium. Nature 1995; 376:66-70; PMID:7596436; http://dx.doi.org/10.1038/376066a0
   PubMed Web of Science ®Google Scholar
• Ciardiello F, Caputo R, Damiano V, Caputo R, Troiani T, Vitagliano D, Carlomagno F, Veneziani BM, Fontanini G, Bianco AR., et al. Antitumor effects of ZD6474, a small molecule vascular endothelial growth factor receptor tyrosine kinase inhibitor, with additional activity against epidermal growth factor receptor tyrosine kinase. Clin Cancer Res 2003; 9:1546-56; PMID:12684431
   PubMed Web of Science ®Google Scholar
• Ciardiello F, Bianco R, Caputo R, Caputo R, Damiano V, Troiani T, Melisi D, De Vita F, De Placido S, Bianco AR., et al. Antitumor activity of ZD6474, a vascular endothelial growth factor receptor tyrosine kinase inhibitor, in human cancer cells with acquired resistance to antiepidermal growth factor receptor therapy. Clin Cancer Res 2004; 10: 784-93; PMID:14760102; http://dx.doi.org/10.1158/1078-0432.CCR-1100-03
   PubMed Web of Science ®Google Scholar
• McMahon G. VEGF receptor signaling in tumor angiogenesis. Oncologist 2000; 5 1:3-10; PMID:10804084; http://dx.doi.org/10.1634/theoncologist.5-suppl_1-3
   PubMedGoogle Scholar
• Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W, Berlin J, Baron A, Griffing S, Holmgren E., et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004; 350:2335-42; PMID:15175435; http://dx.doi.org/10.1056/NEJMoa032691
   PubMed Web of Science ®Google Scholar
• Ferrara N, Gerber HP, LeCouter J. The biology of VEGF and its receptors. Nat Med 2003; 9:669-76; PMID:12778165; http://dx.doi.org/10.1038/nm0603-669
   PubMed Web of Science ®Google Scholar
• Ferrara N, Hillan K, Gerber HP, Novotny W. Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer. Nat Rev Drug Discov 2004; 3:391-400; PMID:15136787; http://dx.doi.org/10.1038/nrd1381
   PubMed Web of Science ®Google Scholar
• Keren P, Zhu Z. Development of angiogenesis inhibitors to vascular endothelial growth factor receptor 2. current status and future perspective. Front Biosci 2005; 10:1415-39; PMID:15769635; http://dx.doi.org/10.2741/1629
   PubMed Web of Science ®Google Scholar
• Lee SH. TTAC-0001 (TTAC-0001): a fully human monoclonal antibody targets vascular endothelial growth factor receptor 2 (VEGFR-2). Arch Pharm Res 2011; 34:1223-6; PMID:21910042; http://dx.doi.org/10.1007/s12272-011-0821-9
   PubMed Web of Science ®Google Scholar
• Spratlin JL. Ramucirumab (IMC-1121B): monoclonal antibody inhibition of vascular endothelial growth factor receptor-2. Curr Oncol Rep 2011; 13:97-102; PMID:21222245; http://dx.doi.org/10.1007/s11912-010-0149-5
   PubMed Web of Science ®Google Scholar
• Spratlin JL, Mulder KE, Mackey JR. Ramucirumab (IMC-1121B): a novel attack on angiogenesis. Future Oncol 2010; 6:1085-94; PMID:20624120; http://dx.doi.org/10.2217/fon.10.75
   PubMed Web of Science ®Google Scholar
• Kunkel P, Ulbricht U, Bohlen P, Brockmann MA, Fillbrandt R, Stavrou D, Westphal M, Lamszus K. Inhibition of glioma angiogenesis and growth in vivo by systemic treatment with a monoclonal antibody against vascular endothelial growth factor receptor-2. Cancer Res 2001; 61:6624-8; PMID:11559524
   PubMed Web of Science ®Google Scholar
• Witte L, Hicklin DJ, Zhu Z, Pytowski B, Kotanides H, Rockwell P, Böhlen P. Monoclonal antibodies targeting the VEGF receptor-2 (Flk1/KDR) as an anti-angiogenic therapeutic strategy. Cancer Metastases Rev 1998; 17:155-61; PMID:9770111; http://dx.doi.org/10.1023/A:1006094117427
   PubMed Web of Science ®Google Scholar
• Zhu Z, Hattori K, Zhang H, Jimenez X, Ludwig DL, Dias S, Kussie P, Koo H, Kim HJ, Lu D., et al. Inhibition of human leukemia in an animal model with human antibodies directed against vascular endothelial growth factor receptor 2. correlation between antibody affinity and biological activity. Leukemia 2003; 17:604-11; PMID:12646950; http://dx.doi.org/10.1038/sj.leu.2402831
   PubMed Web of Science ®Google Scholar
• Lu D, Jimenez X, Zhang H, Bohlen P, Witte L, Zhu Z. Selection of high affinity human neutralizing antibodies to VEGFR-2 from a large antibody phage display library for antiangiogenesis therapy. Intl J Cancer 2002; 97:393-9; PMID:11774295; http://dx.doi.org/10.1002/ijc.1634
   PubMed Web of Science ®Google Scholar
• Burmester J. Pluckthu A Construction of scFv Fragments from Hybridoma or Spleen Cells by PCR Assembly. In: Kontermann R., Dubel S (eds), Antibody Engineering. Berlin: Springer; 2001; 19-40
   Google Scholar
• Yoo JS, Lee WS, Shim SR, Park MI, Kang JE, Kim DY, Lee JC, Lee DH, Cho DY, Sul SS et al. Korea Research Institute of Bioscience and Biotechnology. Human Monoclonal Antibody Neutralizing Vascular Endothelial Growth Factor Receptor and Use Thereof. Korea Patent, KR, 10-2007-00057719, 2007, 13
   Google Scholar
• Benest AV, Harper SJ, Ylä-Herttuala SY, Alitalo K, Bates DO. VEGF-C induced angiogenesis preferentially occurs at a distance from lymphangiogenesis. Cardiovasc Res 2008; 78:315-23; PMID:18065770; http://dx.doi.org/10.1093/cvr/cvm094
   PubMed Web of Science ®Google Scholar
• Lohela M, Heloterä H, Haiko P, Dumont DJ, Alitalo K. Transgenic induction of vascular endothelial growth factor-C is strongly angiogenic in mouse embryos but leads to persistent lymphatic hyperplasia in adult tissues. Am J Pathol, 2008; 173:1891-901; PMID:18988807; http://dx.doi.org/10.2353/ajpath.2008.080378
   PubMed Web of Science ®Google Scholar
• Anisimov A, Alitalo A, Korpisalo P, Soronen J, Kaijalainen S, Leppanen VM, Jeltsch M, Yla-Herttuala S, Alitalo K. Activated forms of VEGF-C and VEGF-D provide improved vascular function in skeletal muscle. Circ Res, 2009; 104:1302-12; PMID:19443835; http://dx.doi.org/10.1161/CIRCRESAHA.109.197830
   PubMed Web of Science ®Google Scholar
• Ladunga I., Smith R.F. Amino acid substitutions preserve protein folding by conserving steric and hydrophobicity properties. Protein Eng 1997; 10:187-96; PMID:9153083; http://dx.doi.org/10.1093/protein/10.3.187
   PubMedGoogle Scholar
• Ruch C, Skiniotis G, Steinmetz MO, Walz T, Ballmer-Hofer K. Structure of a VEGF-VEGF receptor complex determined by electron microscopy. Nature Struct Mol Biol 2007; 14:249-50; PMID:17293873; http://dx.doi.org/10.1038/nsmb1202
   PubMed Web of Science ®Google Scholar
• Linding R, Russell RB, Neduva V, Gibson TJ. GlobPlot: Exploring protein sequences for globularity and disorder. Nucleic Acids Res 2003; 31:3701-8; PMID:12824398; http://dx.doi.org/10.1093/nar/gkg519
   PubMed Web of Science ®Google Scholar
• Kim DG, Jin YG, Jin JY, Yang HY, Joo KM, Lee WS, Shim SR, Kim SW, Yoo JS, Lee SH, et al., Anticancer activity of TTAC-0001, a fully human anti-vascular endothelial growth factor receptor 2 (VEGFR-2/KDR) monoclonal antibody, is associated with inhibition of tumor angiogenesis. 2015. Unpublished manuscript.
   Google Scholar
• Kanellis J, Fraser S, Katerelos M, Power DA. Vascular endothelial growth factor is a survival factor for renal tubular epithelial cells. Am J Physiol Renal Physiol 2000; 278:F905-915; PMID:10836978
   PubMed Web of Science ®Google Scholar
• Hwang SJ, Choi HH, Kim KT, Hong HJ, Koh GY, Lee GM. Expression and purification of recombinant human angiopoietin-2 produced in chinese hamster ovary cells. Protein Exp Purif 2005; 39:175-83; PMID:15642468; http://dx.doi.org/10.1016/j.pep.2004.09.005
   PubMed Web of Science ®Google Scholar
• Nicosia RF, Ottinetti A. Modulation of microvascular growth and morphogenesis by reconstituted basement membrane gel in three-dimensional cultures of rat aorta: a comparative study of angiogenesis in matrigel, collagen, fibrin, and plasma clot. In Vitro Cell Dev Biol 1990; 26:119-28; PMID:1690206; http://dx.doi.org/10.1007/BF02624102
   PubMed Web of Science ®Google Scholar
• Min JK, Han KY, Kim EC, Kim YM, Lee SW, Kim OH, Kim KW, Gho YS, Kwon YG. Capsaicin inhibits in vitro and in vivo angiogenesis. Cancer Res 2004; 64:644-51; PMID:14744780; http://dx.doi.org/10.1158/0008-5472.CAN-03-3250
   PubMed Web of Science ®Google Scholar